Literature DB >> 15026303

Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

D Dardevet1, M C Moore, D Neal, C A DiCostanzo, W Snead, A D Cherrington.   

Abstract

UNLABELLED: Whether glucagon-like peptide-1 (GLP-1) has insulin-independent effects on glucose disposal in vivo was assessed in conscious dogs by use of tracer and arteriovenous difference techniques. After a basal period, each experiment consisted of three periods (P1, P2, P3) during which somatostatin, glucagon, insulin, and glucose were infused. The control group (C) received saline in P1, P2, and P3, the PePe group received saline in P1 and GLP-1 (7.5 pmol.kg(-1).min(-1)) peripherally (Pe; iv) in P2 and P3, and the PePo group received saline in P1 and GLP-1 peripherally (iv) (P2) and then into the portal vein (Po; P3). Glucose and insulin concentrations increased to two- and fourfold basal, respectively, and glucagon remained basal. GLP-1 levels increased similarly in the PePe and PePo groups during P2 ( approximately 200 pM), whereas portal GLP-1 levels were significantly increased (3-fold) in PePo vs. PePe during P3. In all groups, net hepatic glucose uptake (NHGU) occurred during P1. During P2, NHGU increased slightly but not significantly in all groups. During P3, NHGU increased in PePe and PePo groups to a greater extent than in C, but no significant effect of the route of infusion of GLP-1 was demonstrated (16.61 +/- 2.91 and 14.67 +/- 2.09 vs. 4.22 +/- 1.57 micromol.kg(-1).min(-1), respectively). IN
CONCLUSION: GLP-1 increased glucose disposal in the liver independently of insulin secretion; its full action required long-term infusion. The route of infusion did not modify the hepatic response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026303     DOI: 10.1152/ajpendo.00035.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  25 in total

Review 1.  Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.

Authors:  C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2012-04-27       Impact factor: 10.122

2.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Authors:  J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

3.  Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

Authors:  Claude Knauf; Patrice D Cani; Christophe Perrin; Miguel A Iglesias; Jean François Maury; Elodie Bernard; Fadilha Benhamed; Thierry Grémeaux; Daniel J Drucker; C Ronald Kahn; Jean Girard; Jean François Tanti; Nathalie M Delzenne; Catherine Postic; Rémy Burcelin
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 4.  Regulation of hepatic glucose uptake and storage in vivo.

Authors:  Mary Courtney Moore; Katie C Coate; Jason J Winnick; Zhibo An; Alan D Cherrington
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

Review 5.  Adipose tissue, hormones, and treatment of type 1 diabetes.

Authors:  Subhadra C Gunawardana
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 6.  Benefits of healthy adipose tissue in the treatment of diabetes.

Authors:  Subhadra C Gunawardana
Journal:  World J Diabetes       Date:  2014-08-15

7.  Effect of portal glucose sensing on incretin hormone secretion in a canine model.

Authors:  Dale S Edgerton; Guillaume Kraft; Marta S Smith; Lindsey M Moore; Ben Farmer; Melanie Scott; Mary C Moore; Michael A Nauck; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-05-21       Impact factor: 4.310

8.  Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

Authors:  Marzieh Salehi; Benedict Aulinger; Ronald L Prigeon; David A D'Alessio
Journal:  Diabetes       Date:  2010-03-09       Impact factor: 9.461

9.  Portal glucose infusion-glucose clamp measures hepatic influence on postprandial systemic glucose appearance as well as whole body glucose disposal.

Authors:  Dan Zheng; Viorica Ionut; Vahe Mooradian; Darko Stefanovski; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

10.  Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.

Authors:  Dale S Edgerton; Zhibo An; Kathryn M S Johnson; Tiffany Farmer; Ben Farmer; Doss Neal; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-14       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.